Corneal Versus Conjunctival Delivery Using a Delivery Device

This study has been withdrawn prior to enrollment.
Information provided by:
Pfizer Identifier:
First received: September 1, 2005
Last updated: March 1, 2007
Last verified: October 2006

Compare the antihypertensive efficacy of three methods for installing Xalatan

Condition Intervention Phase
Glaucoma, Open-Angle
Ocular Hypertension
Drug: Xalatan
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Single Blind
Primary Purpose: Treatment
Official Title: Effect Of Corneal Versus Conjunctival Delivery On The Corneal Safety, Tolerability, and Antihypertensive Efficacy Of The Xalatan Ophthalmic Delivery Device

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • IOP level in the study eye

Secondary Outcome Measures:
  • Change in ocular safety assessments. Ocular and systemic adverse events throughout the study period

Estimated Enrollment: 42

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of primary open angle glaucoma or ocular hypertension in 1 or both eyes

Exclusion Criteria:

  • History of closed/barely open anterior chamber angle or a history of angle closure
  Contacts and Locations
Please refer to this study by its identifier: NCT00143429

Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

No publications provided Identifier: NCT00143429     History of Changes
Other Study ID Numbers: A6111127
Study First Received: September 1, 2005
Last Updated: March 1, 2007
Health Authority: United States: Food and Drug Administration

Keywords provided by Pfizer:
Primary Open Angle Glaucoma

Additional relevant MeSH terms:
Glaucoma, Open-Angle
Ocular Hypertension
Eye Diseases
Vascular Diseases
Cardiovascular Diseases
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions processed this record on April 14, 2014